Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M

Core Insights - The company reported strong growth in Q4 2025, particularly in its Acute Care franchise, with notable contributions from ZYNRELEF and APONVIE [1] - Overall revenue for Q4 was approximately $40.5 million, with a total net revenue of about $154.9 million for FY25 [1] Financial Performance - Q4 net revenue: approximately $40.5 million for the three months ended December 31 [1] - ZYNRELEF net revenue: approximately $12.5 million for Q4 [1] - APONVIE net revenue: approximately $3.8 million for Q4 [1] - CINVANTI net revenue: approximately $22.9 million for Q4 [1] - SUSTOL net revenue: approximately $1.3 million for Q4 [1] - FY25 total net revenue: approximately $154.9 million [1] - ZYNRELEF experienced the largest quarter-over-quarter revenue increase within the portfolio in Q4 [1]